Goutham Sunny

🤩 Finally OUT in @JCO_ASCO! BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy A decade of persistence from @VedangMurthy ☺️ @RadOncTMC @TataMemorial @ACTREC_TMC @PaulSargos @Xristodouleas ascopubs.org/doi/full/10.12…

FDA approves Dato-DXd (Datroway) for 1L metastatic TNBC in patients ineligible for immunotherapy (70% of pts). Now we have 2 TROP2 ADCs in same indication; we can only use 1 upfront. TROPION-Breast02 vs ASCENT-03: similar PFS (10.8 vs 9.7 mo), OS (23.7 vs 21.5 mo), and DOR (12.3 vs 12.2 mo). Dato-DXd showed higher ORR (62.5% vs 48%), a very different side effect profile (stomatitis/dry eye vs neutropenia/diarrhea), Q3W vs days 1+8 dosing. Nice brain metastases activity with Dato-DXd; HR of 0.3 in the brain mets subgroup. DFI pts <6 months only included in Dato-DXd trial. For IO-ineligible mTNBC, we have two nice options. #TNBC #breastcancer #oncology

Please urge everyone to sit down spend an hour reading the AQUILA trial before blindly listening to experts and prescribing daratumumab for smoldering myeloma.

DatoDXd now @US_FDA ✅ in 1L mTNBC in PDL1 negative/IO ineligible based off TROPION-Breast02 - mPFS 10.8 vs 5.6mos (HR: 0.57) - mOS 23.7 vs. 18.7mos (HR: 0.79) - ORR 62.5% vs. 29.3% - Common AEs: mucositis & occular AEs #OncTwitter #bcsm @OncUpdates

1/ASCO 2026 is days away and your feed is filling with "abstracts/presentation I'm most excited about." My pick is ...probably on nobody's list. The whole story is about one dose. Give me 90 seconds. It may worth a read.

This is far more than just another #FDA update; it’s a total rewrite of the first-line standards for Triple-Negative Breast Cancer (TNBC)! For metastatic TNBC patients who aren't eligible for immunotherapy, we have historically relied on standard chemotherapy. The approval of the TROP2-directed ADC Datopotamab Deruxtecan (Dato-DXd) shatters that ceiling. #BreastCancer #TNBC #Oncology #MedTwitter #FDAApproval

Head & Neck Cancer #ASCO2026 oral abstracts in a nutshell: No breakthroughs—but pragmatic progress with emerging signals of what’s next.

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/pdf/10.120… @JCOOP_ASCO @ASCO @OncoAlert one of the most common consults in General HemOnc Clinics

So now even taxanes supply is under threat. If the authorities can’t ensure that stocks of non expensive essential life saving cancer drugs are restored, request them to atleast issue an official legal order that absolves medical oncologists from the legal liability of inferior treatments and outcomes thanks to national shortage of these drugs, coz while we would very much like saving lives, when that is not facilitated by the Government and the global situation, we would very much like to atleast save our @$$! @MoHFW_INDIA @PMOIndia @JPNadda

In oncology we say one size doesn’t fit all, but if there are any drugs that work in almost all cancers, they have to be platinum drugs especially Cisplatin and Carboplatin. The simplest, effective and cheapest drugs that have no replacement in several cancers are out of stock in most hospitals in India, leaving patients and families to suffer with no treatments even in curable cancers. The global supply chain has been massively impacted, so are the import rates and manufacturing rates. While capping prices of drugs is a welcome move, flexibility that is reviewed dynamically is the need of the hour, a 50% rise in capped price of a 200 rupees drug that is life saving should be accommodated as the cost of lives lost is going to be much more. Request @narendramodi @PMOIndia @JPNadda @MoHFW_INDIA @AmitShahOffice to resolve the situation ASAP

This is a global issue for both Cisplatin and carboplatin .. @ChandrakanthMv needs to be highlighted … affecting so many pts @AyushmanNHA @CancerGridIndia @cspramesh @ASCO @DrSanjayPopat @myESMO … not an expensive drug so industry not bothered. @PMOIndia @JPNadda @ICMRDELHI @jrgralow @drkiwicj

Reviewing 1L options in advanced #HCC Atezo Bev still has the strongest signal and longest followup - across multiple subsets. ✅ AFP>400 ✅ Vp4 portal invasion ✅ Viral HCC ❓MAFLD ❓ Fibrolamellar TKIs with signals - Sora, Lenva, Cabo, Regora @OncoDailyGI @oncodaily #cancer

One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 aacrjournals.org/cancerres/arti…

Never forget this. Time is finite... Family always comes first. Courtesy @jenna_taglienti

Excited to share our new publication in Expert Opinion on Investigational Drugs: We discuss the role of CDK8/19 in AML transcription and early clinical data on romaciclib, including promising combinations with venetoclax in relapsed/refractory disease. tandfonline.com/doi/full/10.10…

Let's review the mech of Gonadotoxicity in #lymphoma Rx - ROS+direct damage ❌ Worst culprits - Alkylators - Procarbazine & cyclophos 👀 Jury's out on long term data - relatively safe - BV, Nivo, Pembro ⚠️ Teratogenicity - Etopo, Len #medtwitter #oncology #cancer #fertility

Let's review a few important uncommon mutations in #nsclc #lung #cancer MET, RET, KRAS, HER2, BRAF, HER2 Watch out for edema, HTN, pneumonitis with the MET/RET mTKIs! #lcsm #medtwitter #onctwitter (Slide 2 courtesy Dr Sumit, Shillong)

🧬✨ Just published: ESMO Guidelines 2026 in mCRC 📊 Molecular-driven algorithm consolidated 🧪 Mandatory profiling → RAS/BRAF, MSI, HER2 ±NGS 🎯 1L by biology → MSI-H: ICI | RAS wt left: anti-EGFR 💊 3L+ → FTD/TPI + BEV preferred 💥 Precision + sequencing redefine SoC 🔗 annalsofoncology.org/action/showPdf… @OncoAlert

Algorithm for Systemic Therapy in Early HR+/HER2- Breast Cancer (Recommendations in gray areas reflect my own clinical judgment— eg. olaparib and CDK4/6 sequence)

Algorithm for Systemic Therapy in Early TNBC (Based on NCCN and ESMO guidelines; recommendations in gray areas reflect the St. Gallen 2025 consensus and, in part, my own clinical judgment)